Bladder Tumor Organoid Model: A Method for Orthotopic Transplantation of Bladder Organoids into Recipient Murine Bladder
JoVE Encyclopedia of Experiments
Cancer Research
0 views • 4:15 min • April 30th, 2023
Loading...
Overview
This article discusses the development of patient-derived tumor organoids, which are miniature tumors that retain the characteristics of the original tumor. These organoids are used for personalized cancer therapy, particularly in bladder cancer.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Translational Medicine
Background
- Patient-derived tumor organoids are created from the parent tumor.
- They maintain phenotypic and genetic characteristics of the original tumor.
- These organoids facilitate personalized cancer treatment strategies.
- Bladder cancer organoids are specifically highlighted for their cellular marker similarities.
Purpose of Study
- To develop a reliable model for studying bladder cancer.
- To enable the integration of organoids into animal models for research.
- To enhance personalized treatment approaches using organoid technology.
Methods Used
- Culture of bladder tumor organoids with collagenase enzyme treatment.
- Injection of organoid suspension into the bladder of anesthetized mice.
- Use of basement membrane matrix to facilitate organoid integration.
- Surgical techniques for orthotopic transplantation into the bladder wall.
Main Results
- Successful retention of tumor characteristics in organoids post-transplantation.
- Integration of organoids into the bladder wall mimicking the parental tumor microenvironment.
- Demonstrated potential for personalized cancer therapy using organoid models.
- Methodology established for future research in bladder cancer.
Conclusions
- Patient-derived organoids are effective for studying bladder cancer.
- They provide a platform for personalized treatment strategies.
- The methodology can be adapted for other cancer types.
Frequently Asked Questions
What are patient-derived tumor organoids?
They are miniature tumors developed from the parent organ that retain the original tumor's characteristics.
How are organoids prepared for transplantation?
Organoids are cultured, treated with collagenase, and injected into the bladder of anesthetized mice.
What is the significance of using basement membrane matrix?
It helps entrap the organoids and facilitates their integration with the bladder wall.
Can this method be used for other types of cancer?
Yes, the methodology can be adapted for studying other cancer types.
What are the benefits of using organoids in cancer research?
They allow for personalized treatment approaches and better mimic the tumor microenvironment.
How do organoids contribute to personalized cancer therapy?
They retain the genetic and phenotypic characteristics of the original tumor, enabling tailored treatment strategies.
Executive Industry Relevance
Orthotopic transplantation of bladder tumor organoids enables physiologically relevant modeling of tumor-stroma interactions in vivo. This approach supports mechanistic de-risking of bladder cancer therapeutics by preserving native tumor architecture and microenvironmental cues. It provides a predictive preclinical system for evaluating drug response and tumor progression in a clinically translatable context.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of bladder cancer targets within an intact tissue microenvironment.
- Operational Value: Maintains tumor heterogeneity and stromal interactions lost in monolayer cultures.
- Strategic Value: Improves target confidence by linking molecular perturbations to phenotypic outcomes in situ.
Screening & Assay Development
- Scientific Value: Supports dose-response assessment of compounds in a 3D architecture that mimics in vivo drug penetration.
- Operational Value: Generates quantifiable endpoints such as tumor engraftment and growth kinetics.
- Strategic Value: Enhances predictive confidence in lead identification by reducing false positives from artificial culture systems.
Translational & Preclinical Research
- Scientific Value: Models orthotopic tumor growth and invasion patterns relevant to human bladder cancer pathogenesis.
- Operational Value: Facilitates longitudinal monitoring of tumor development using imaging or biomarker readouts.
- Strategic Value: Informs go/no-go decisions by demonstrating target modulation in a clinically relevant anatomical site.
Pipeline & Workflow Integration
The method bridges early discovery and preclinical validation by providing a reproducible orthotopic model for bladder cancer target evaluation.
- Discovery Biology: Supports hypothesis testing of tumor-stroma interactions and microenvironment-dependent signaling pathways.
- Screening: Enables compound screening in a preserved extracellular matrix context affecting drug accessibility and efficacy.
- Analytics: Delivers quantitative outputs including organoid engraftment efficiency and tumor volume over time.
- Translational Research: Aligns with biomarker studies by maintaining original tumor molecular signatures post-transplantation.
- Enterprise Reuse: Establishes a standardized platform for iterative target validation across bladder cancer subtypes.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by preserving native tumor architecture and stromal composition.
- Operational Value: Ensures reproducibility through standardized enzymatic dissociation and matrix embedding protocols.
- Strategic Value: De-risks target selection by demonstrating phenotypic response in an orthotopic setting.
- Portfolio Impact: Enables risk-adjusted prioritization of bladder cancer therapeutics based on in vivo-like efficacy data.
Implementation Considerations
- Requires expertise in organoid culture, microsurgery, and anesthesia management in murine models.
- Dependent on access to basement membrane matrix (e.g., Matrigel) and collagenase/dispase for organoid preparation.
- Necessitates aseptic surgical technique and postoperative monitoring for engraftment success.
- Limited by organoid viability during preparation and injection, requiring cold-chain handling until transplantation.
- Scalability constrained by murine surgical throughput and postoperative recovery timelines.
Biopharma FAQs
Why is orthotopic transplantation critical for bladder tumor organoid validation?
Orthotopic transplantation ensures organoids integrate into the native bladder wall microenvironment, preserving stromal interactions and tumor architecture. This approach maintains phenotypic and genetic fidelity to the parental tumor, enabling physiologically relevant modeling of tumor progression. It supports target validation by reflecting in vivo-like responses to therapeutic perturbations.
How does collagenase/dispase treatment enable organoid preparation for transplantation?
Collagenase/dispase enzymatically degrades extracellular matrix components to release free organoids from culture while preserving their structural integrity. This step generates a uniform organoid suspension suitable for resuspension in basement membrane matrix. The process ensures minimal organoid damage and maintains viability for subsequent injection.
What quantitative measurements assess successful engraftment of bladder tumor organoids?
Engraftment success is evaluated by organoid retention in the bladder wall, tumor formation over time, and histopathological confirmation of invasive growth. Tumor volume and growth kinetics serve as quantifiable endpoints for therapeutic response assessment. These measurements enable comparison across treatment groups in preclinical studies.
Why is replication required in orthotopic organoid transplantation studies?
Replication accounts for biological variability in organoid engraftment, tumor take rate, and host microenvironmental differences. Consistent results across replicates increase confidence in target modulation phenotypes and reduce false-positive findings. It supports cross-functional alignment by providing robust data for go/no-go decisions in drug discovery.
What statistical analyses are needed before implementing organoid transplantation in target validation workflows?
Pre-implementation requires power analysis to determine appropriate group sizes based on expected engraftment variability and effect size. Post-transplantation data should be analyzed using parametric or non-parametric tests depending on distribution normality, with correction for multiple comparisons when evaluating several targets. These analyses ensure statistical rigor in interpreting tumor growth inhibition or progression metrics.
07:33
In vitro Organoid Culture of Primary Mouse Colon Tumors
Related Videos
0 Views
06:19
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Related Videos
0 Views
08:54
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
Related Videos
0 Views
09:07
An Orthotopic Model of Murine Bladder Cancer
Related Videos
0 Views
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Related Videos
0 Views
04:28
Modeling Orthotopic Bladder Tumor in Mouse Model: A Procedure for Intravesical Administration of Cancer Cells into Murine Bladder
Related Videos
0 Views
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Related Videos
0 Views
08:15
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
Related Videos
0 Views
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Related Videos
0 Views
09:28
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Related Videos
0 Views
Last updated: 1 August 2026